The initiative was founded in 2015, by Dr. Priscilla Chan and her spouse Mark Zuckerberg, the co-founder and CEO of Facebook.
The FlexArm gantry enables clinicians to quickly and easily visualize critical anatomy and identify changes to a patient during a procedure.
FDA has warned several facilities against illegally marketing and distributing unapproved thermography devices as a sole screening device for breast cancer and other diseases.
The John Wayne Cancer Institute in Santa Monica, CA and Maimonides Medical Center in Brooklyn, NY were the first two hospitals to adopt EDAP TMS’ new Focal One device — an advanced ultrasound technology that can be used to target and ablate diseased tissue.
University of Wisconsin School of Medicine and Public Health Researchers are using positron emission tomography with 18F-fluorofuranylnorprogesterone to give better insight on hormonal therapies for the treatment of breast cancer.
Duke University Medical Center researchers looked at data from 9,000 patients who underwent Cardiac Magnetic Resonance.
Acutus Medical originally received a nod from FDA in 2017 and a CE mark in 2016 for the AcQMap cardiac imaging technology.
The imaging process was developed by a team of researchers from Northwestern University and could help lead to the early diagnosis of disease.
An artificial intelligence solution that can identify precancerous changes in a woman’s cervix, comes on the heels of a Mayo Clinic Study that shows the percentage of women who are screened for cervical cancer could be far lower than national data suggests.
Infervision’s deep-learning system alerts radiologists to the possible presence of four different diseases, which could lead to faster and more comprehensive diagnoses.
With the explosion of artificial intelligence and its overall acceptance in healthcare along with strong data supporting the WATS3D test, could 2019 be a breakthrough year for CDx Diagnostics.
Osaka University researchers have developed an AI-based system that has the potential to differentiate between different types of cancer cells. The research could have major implications in the field of oncology.
CLARITY enables the formation of a hydrogel matrix by crosslinking biological molecules to a 3D network of hydrophilic polymers followed by lipid removal to generate a transparent, structurally intact tissue. The tissue retains its original structural features, can be labeled with macromolecules, and subsequently imaged without destruction of tissue morphology.
The Los Altos, CA-based company has raised $20 million in a series C round to help with market adoption of its Triton solution.